检索

期
标题
作者
卷 30, 编号 3 (2023)
Modern practice of lipid-lowering pharmacotherapy: the choice of the optimal fixed combination
Biryukova E., Shinkin M., Morozova I.
PDF
(Rus)
卷 30, 编号 1/2 (2023)
Relationship between non-alcoholic fatty liver disease and cardiovascular disease: focus on the use of ursodeoxycholic acid
Polyakova O., Tkachenko Y., Ostroumova O.
PDF
(Rus)
卷 30, 编号 14 (2023)
Bempedoic acid – a new drug in lipid-lowering therapy
Leonova M.
PDF
(Rus)
编号 9 (2017)
PROBLEMS OF COMORBID PATIENT AND POLYPRAGMASY IN NEUROLOGY
Shishkova V.
PDF
(Rus)
编号 2 (2017)
Nonalcoholic fatty liver disease and cardiovascular risk (literature review)
Shirokova E.
PDF
(Rus)
编号 1 (2009)
Cardio-vascular diseases in post-menopause (problems and ways of their solution)
Kirichenko A., Kirichenko A.
卷 29, 编号 3 (2022)
Drug safety in real clinical practice: focus on protective therapy
Trukhan D., Ivanova D.
PDF
(Rus)
编号 20 (2010)
EFFICACY OF OMEGA-3 POLYUNSATURATED FATTY ACID FOR PRIMARY AND SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES: CURRENT STATE OF THE PROBLEM
Gilyarevskiy S., Gilyarevsky S.
卷 29, 编号 4 (2022)
Efficacy and safety of ertugliflozin: results of the VERTIS CV sub-study in patients receiving a stable dose of insulin
Novikova M., Koteshkova O., Antsiferov M.
PDF
(Rus)
卷 27, 编号 13 (2020)
The role of the disturbances in the intestinal barrier structure in relation to cardiovascular diseases pathogenesis and rebamipid potential in their correction
Ostroumova O., Kochetkov A.
PDF
(Rus)
编号 20 (2016)
CARDIORENAL RELATIONSHIPS IN PATIENTS WITH PRIMARY HYPOTHYROIDISM DEPENDING ON THE PHASE OF DISEASE
Nikolaeva A., Pimenov L.
PDF
(Rus)
编号 15 (2010)
NONALCOHOLIC FATTY LIVER DISEASE AND CARDIOVASCULAR RISK: INFLUENCE OF FEMALE SEX
Drapkina O., Korneev O., Drapkina O., Korneeva O.
编号 15 (2009)
Arterial hypertension: importance of individual drugs selection and place of angiotensin-converting enzyme inhibitors in the treatment
Martynov A., Martinov A.
卷 28, 编号 12 (2021)
Possibilities of dapagliflozin in cardio-reno-metabolic protection in patients with and without type 2 diabetes mellitus
Antsiferov M., Koteshkova O., Novikova M., Demidov N.
PDF
(Rus)
编号 3 (2012)
TYPE 2 DIABETES MELLITUS AND CONCOMITANT DISEASES: ADVANTAGES OF USE OF DIPEPTIDYL PEPTIDASE-4 INHIBITOR SAXAGLIPTIN (ONGLYZA ®)
Antsiferov M., Petunina N., Antsiferov M., Petunina N.
编号 15 (2009)
Insulin resistance and heart diseases: is there a relationship?
Drapkina O., Smirin V., Ivashkin V., Drapkina O., Smirin V., Ivaschkin V.
卷 27, 编号 5 (2020)
Beta-blockers in patients with chronic obstructive pulmonary disease: for whom, when, how?
Karoli N., Rebrov A.
PDF
(Rus)
编号 15 (2009)
Phytosterins and cardiovascular diseases
Perova N., Perova N.
编号 2s (2013)
SERDEChNO-SOSUDISTYE ZABOLEVANIYa I OSTEOPOROZ
Karpova N., Rashid M., Shostak N., Kazakova T.
PDF
(Rus)
编号 15 (2011)
PLACE OF ASPIRIN IN THE THERAPY OF ATHEROTHROMBOSIS AND ITS COMPLICATIONS
Gilyarov M., Gilyarov M.
编号 8 (2010)
Hawthorn (Crataegus): options for medical use
Samylina I., Sorokina A., Pyatigorskaya N., Samylina I., Sorokina A., Pyatigorskaya N.
编号 17 (2012)
Sovremennye podkhody k lecheniyu dislipidemiy: differentsirovannaya gipolipidemicheskaya terapiya
Lupanov V.
PDF
(Rus)
卷 29, 编号 11/12 (2022)
Hypothyroidism is an untimely diagnosed disease
Verbovoy A., Verbovaya N., Sharonova L.
PDF
(Rus)
卷 28, 编号 3 (2021)
The relationship of cardiovascular disease with increased intestinal permeability: results from scientific and controlled clinical trials. Focus on the potential of rebamipide
Ostroumova O., Kochetkov A., Pavleeva E., Golovina O., Arablinsky N.
PDF
(Rus)
编号 16 (2017)
Polymorbidity and modern medicine
Verbovoy A., Tsanava I., Verbovaya N., Galkin R., Madyanov I.
PDF
(Rus)
编号 16 (2016)
Diabetes mellitus and coronary artery disease: features of clinical manifestation and treatment
Verbovoy A., Sharonova L.
PDF
(Rus)
编号 15 (2013)
Vozmozhnosti primeneniya beta-adrenoblokatorov v lechenii serdechnososudistykh zabolevaniy u bol'nykh khronicheskoy obstruktivnoy bolezn'yu legkikh
Statsenko M., Derevyanchenko M.
PDF
(Rus)
编号 6 (2009)
Anxiety and depression as risk factors of cardiovascular diseases: possibilities of medicamentous correction
Makolkin V., Makolkin V.
卷 29, 编号 6 (2022)
Is there a «window of therapeutic opportunity» for testosterone replacement therapy for age-related hypogonadism in men?
Apetov S., Apetova V.
PDF
(Rus)
编号 15 (2017)
Energy metabolism corrector Mildronate®: interrelation of mechanisms of action and therapeutic effects
Dzerve V.
PDF
(Rus)
编号 7 (2010)
Psychiatric disturbances in cardiological practice
Artyukhova M., Artuhova M.
1 - 31 的 31 信息

检索提示:

  • 检索的名词区分大小写
  • 常用字词将被忽略
  • 默认情况下只有在查询结果满足所有检索词才返回（例如，隐含AND）
  • 使用OR结合多个检索词，便于查找含有这些检索词的文章，例如education OR research
  • 使用括号来创建更复杂的查询; 例如：archive ((journal OR conference) NOT theses)
  • 使用引号检索一个完整的词组; 例如： "open access publishing"
  • 使用-或者NOT排除一个检索词; 例如：online -politics or online NOT politics
  • 在检索词里使用 *作为通配符匹配任何字符序列; 例如., soci* morality 将符合含有 "sociological" or "societal"的词语
##common.cookie##